Loading…
Favipiravir Tablets 400mg (Fabitaj) Favipiravir Tablets 400mg Favipiravir Tablets 400mg Favipiravir Tablets 400mg Favipiravir Tablets 400mg Favipiravir Tablets 400mg Favipiravir Tablets 400mg Favipiravir Tablets 400mg Favipiravir Tablets 400mg Favipiravir Tablets 400mg Favipiravir Tablets 400mg Favipiravir Tablets 400mg Favipiravir Tablets 400mg Favipiravir Tablets 400mg Favipiravir Tablets 400mg Favipiravir Tablets 400mg
Categories: , , , ,
Date:

Favipiravir Tablets 400mg Technical Specification:

Product Name:Favipiravir Tablets 400mg
Brand Name:Fabitaj
Strength:200mg, 400mg, 800mg
Dosage Form:Film-coated Tablet
Packing:10s, 17s, 34s
Route of Administration:For Oral Use only.
Pack Insert/Leaflet:PIL (Patient Information Leaflet), SmPC (Summary Product Characteristics)
Regulatory Documents:COA, MOA, COPP, FSC, Stability Studies, GMP, CTD Dossier
Therapeutic use:Antiviral
Indication: Favipiravir is uses in the treatment of influenza, Ebola and other pathogenic viral infections. It is also being studied to treat a number of other viral infections, including SARS-CoV-2
Storage:Store at a temperature not exceeding 25°C. Protect from moisture

GENERIC NAME OF THE MEDICINAL PRODUCT:

  • Favipiravir Tablets 400mg

QUALITATIVE AND QUANTITATIVE COMPOSITION:

  • Favipiravir Tablets 400mg
    Each film-coated tablet contains:
    Favipiravir……………………….400mg
    Excipients………………………. q.s.
    Colours: Red oxide of Iron

THERAPEUTIC INDICATIONS:

Favipiravir is uses in the treatment of influenza, Ebola and other pathogenic viral infections. It is also being studied to treat a number of other viral infections, including SARS-CoV-2.

Favipiravir tablets used for the treatment of mild to moderate COVID-19 disease in adults under restricted emergency use.

CAUTION & WARNING:

CAUTION: Swallow complete tablet, do not crush or chew.

Read enclosed leaflet before use.

Keep medicine out of reach of children.

Warning: Do not administer the drug to women known or suspected to be pregnant

Warning: Male patient should use most effective contraceptive methods in sexual intercourse during and for 7 days after the end of treatment.

Warning: To be sold by retail on the prescription of a Registered Medical Practitioner only.

STORAGE & DOSAGE:

Storage:  Store at 20-25°C (68-77°F) [see USP Controlled Room Temperature].

Dosage:  As directed by the Physician.

Attach dispensing label as per end country.

NOTE: 14-day oral administration of favipiravir at a dose of 30 mg/kg/day.

GENERIC NAME OF THE MEDICINAL PRODUCT:

A. Favipiravir Tablets 200mg
B. Favipiravir Tablets 400mg
C. Favipiravir Tablets 800mg

QUALITATIVE AND QUANTITATIVE COMPOSITION:

A. Favipiravir Tablets 200mg
Each film-coated tablet contains:
Favipiravir………………...…….200mg
Excipients………………………. q.s.
Colours: Titanium Dioxide USP

B. Favipiravir Tablets 400mg
Each film-coated tablet contains:
Favipiravir……………….…….400mg
Excipients………………………. q.s.
Colours: Red oxide of Iron

C. Favipiravir Tablets 800mg
Each film-coated tablet contains:
Favipiravir……………….…….800mg
Excipients………………………. q.s.
Colours: Yellow oxide of Iron

THERAPEUTIC INDICATIONS:

Favipiravir is uses in the treatment of influenza, Ebola and other pathogenic viral infections. It is also being studied to treat a number of other viral infections, including SARS-CoV-2.
Favipiravir tablets used for the treatment of mild to moderate COVID-19 disease in adults under restricted emergency use.

CAUTION & WARNING:

CAUTION: Swallow complete tablet, do not crush or chew.
Read enclosed leaflet before use.
KEEP MEDICINE OUT OF REACH OF CHILDREN.
WARNING: Do not administer the drug to women known or suspected to be pregnant.
WARNING: Male patient should use most effective contraceptive methods in sexual intercourse during and for 7 days after the end of treatment.
WARNING: To be sold by retail on the prescription of a Registered Medical Practitioner only.

STORAGE & DOSAGE:

Storage: Store at 20-25°C (68-77°F) [see USP Controlled Room Temperature].
Dosage: As directed by the Physician.
Attach dispensing label as per end country.
NOTE: 14-day oral administration of favipiravir at a dose of 30 mg/kg/day.